Zebrafish are an emerging power tool in cancer research. They can be engineered to light up when certain genes turn on — capturing the moment when a cancer is initiated. Because they breed so quickly, they lend themselves to rapid, large-scale chemical screening studies, so can help identify tumor promoters and suppressors. Now, as a new study in Science demonstrates, zebrafish can also help scientists dissect the intricate molecular pathways that underlie many cancers, and could help guide treatment strategies — in this case, for mucosal melanoma.
Mucosal melanomas are rare tumors found not on the skin, but in the linings of the respiratory tract, mouth, GI tract and genitourinary tract. They tend to come to light only when very advanced. Their biology is poorly understood, and they tend to lack the genetic mutations associated with skin melanomas. Thus, few patients benefit from targeted therapies. The five-year survival rate is only 33 percent.
That’s where Leonard Zon, MD, and his colleagues at Boston Children’s Hospital thought they could help. Zon’s lab had already developed a zebrafish melanoma model that faithfully simulates human melanoma tumors and is easy to manipulate genetically. Could it shed new light on mucosal melanomas?
“Zebrafish offer the ability to test genetic hypotheses quite rapidly,” says Julien Ablain, PhD, a fellow in the lab. “Genetic sequencing gives you a lot of information, but not a functional understanding of what the genetic alterations do. Our melanoma model allows us to ask these questions in large numbers of fish — and make statistically significant observations.”
Modeling mucosal melanoma in zebrafish
The Boston Children’s team approached the lab of Iwei Yeh, MD, PhD at the University of California San Francisco (UCSF), known for having sequenced many different melanoma tumors. The lab indeed had a cohort of 43 patients with mucosal melanomas, as well as sequencing data.
Analyzing these data for point mutations and DNA deletions and duplications, the researchers saw some intriguing clues. The top alteration involved a gene called SPRED1, never before implicated in cancer. It was inactivated in 37 percent of mucosal melanomas, but only 5 percent of skin melanomas. The mucosal tumors were also more likely than skin melanomas to harbor alterations in KIT, a known oncogene.
Zon’s group then took these genetic observations into their zebrafish. The scientists injected the fish en masse as embryos, so the same genetic changes found in human patients were reproduced in every zebrafish melanin-producing cell. This allowed them to model the effects of all the combinations of genetic alterations that occurred together with SPRED1 loss in the 43 UCSF patients.
Mixing and matching mutations
Cancers often arise from a one-two genetic hit: activation of a tumor-promoting gene plus loss of a tumor suppressor gene. So the Zon lab created a system to mix and match mutations. They used one vector to introduce oncogenes into the fish that are known to be relevant to human mucosal melanoma (namely, KIT, BRAF and NRAS). Another vector used CRISPR technology to delete known tumor suppressors (namely, tp53, pten and cdkn2a). In all, they tested 15 to 20 combinations of oncogenes and tumor suppressors.
Within 1 to 4 months, all the combinations had been tested. The tumors that arose in the fish resembled human mucosal melanomas, appearing in non-skin locations including internal organs.
Zebrafish that also had SPRED1 deletions had more severe melanomas, indicating that SPRED1 is a previously unrecognized tumor suppressor. Loss of SPRED1 was especially damaging in fish with KIT mutations: their melanomas were even more severe.
Dissecting melanoma biology
The team then switched from studying zebrafish to studying human mucosal melanoma cell lines. This allowed them to delve into the cancer’s biology and to understand SPRED1’s role and its interplay with KIT.
When Ablain and colleagues inactivated SPRED1, the melanoma cells proliferated faster. The reverse was also true. “If you overexpress SPRED1 in a KIT-driven zebrafish melanoma model, you delay melanomas,” says Ablain. “That confirms that SPRED1 acts as a tumor suppressor.”
Loss of SPRED1 increased the activity of a cellular pathway called MAPK, known to be associated with skin melanomas — especially in tumors driven by KIT, which is part of the same pathway.
“Before, it was unclear whether the mucosal subtype of melanomas was driven by MAPK activity,” says Ablain. “Our data suggest that they are, even though the genetic alterations are different.”
The experiments also showed that when SPRED1 is lost, tumors become resistant to compounds that inhibit KIT. This suggests that patients with SPRED1 deletions wouldn’t benefit from existing KIT inhibitors. But they could potentially benefit from other drugs that inhibit the MAPK pathway downstream of KIT, such as MEK inhibitors. To test that prediction, the researchers plan to collaborate with the Dana-Farber Cancer Institute. They will look at past clinical trials involving patients with mucosal melanoma to see if they had SPRED1 deletions and whether they benefited from KIT inhibitors.
Zon’s lab also plans to look for SPRED1 alterations in other kinds of tumors. Currently, SPRED1 isn’t part of the panel of cancer-related genes often used to test patients, notes Ablain.
“For targeted therapies, you really need to understand the molecular mechanism,” he says. “That is the first thing this paper is going to change.”
“This paper establishes the zebrafish as an extremely quick model to study the many genes mutated and regulated in human cancer,” says Zon, who is director of the Stem Cell Research Program at Boston Children’s Hospital and a senior physician with the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. “In the future, patients could have their specific mutations modeled in zebrafish to guide decisions about their treatment.”
Ablain and Mengshu Xu of UCSF were co-first authors on the paper. Zon and Iwei Yeh of UCSF were co-senior authors. The study was funded by the Melanoma Research Foundation, the Dermatology Foundation, the Melanoma Research Alliance, the Ellison Foundation, the Starr Foundation, the V Foundation, the Terry Patters Melanoma Foundation, the National Cancer Institute and the Howard Hughes Medical Institute.